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Effects of transforming growth factor beta-1 on growth-regulatory genes
in tumour-derived human oral keratinocytes
IC Paterson, V Patel, JR Sandy, SS Prime and WA Yeudall*
Department ofOral andDental Science, Division ofOral Medicine, Pathology and Microbiology, University ofBristol Dental
Hospital and School, Lower Maudlin Street, Bristol BSJ 21 Y UK.
Summary This study examined the effect of transforming growth factor beta-I (TGF-PI) on c-myc, RBI,
junB and p53 expression together with pRb phosphorylation, in carcinoma-derived and normal human oral
keratinocytes with a range ofinhibitory responses to this ligand. Amplification of c-myc was observed in eight
of eight tumour-derived cell lines and resulted in corresponding mRNA expression. The down-regulation of
c-myc expression by TGF-P1 predominantly reflected growth inhibition by TGF-p1, but in two of eight
tumour-derived cell lines which were partially responsive to TGF-Pl c-myc expression was unaltered by this
ligand. While RBI mRNA levels were unaltered by TGF-p1, the ligand caused the accumulation of the
underphosphorylated form of the Rb protein in all cells irrespective of TGF-P1-induced growth arrest. junB
expression was up-regulated by TGF-Pl in cells with a range of growth inhibitory responses. All cells
contained mutant p53. TGF-Pl did not affect p53 mRNA expression in both tumour-derived and normal
keratinocytes and there was no alteration in p53 protein levels in keratinocytes expressing stable p53 protein
following TGF-P1 treatment. The data indicate that TGF-p-induced growth control can exist independently of
the presence of mutant p53 and the control of Rb phosphorylation and c-myc down-regulation. It may be that
TGF-P growth inhibition occurs via multiple mechanisms and that the loss of one pathway during tumour
progression does not necessarily result in the abrogation of TGF-p-induced growth control.
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The human transforming growth factor beta family of
growth factors (TGF-p1, P2, 133) are highly conserved, ubi-
quitous peptides that exhibit a remarkable diversity of
biological action, notably the inhibition of epithelial cell
growth. Many malignant human epithelial cell lines are either
refractory or partially responsive to TGF-11, possibly owing
to the accumulation of multiple genetic defects (Fynan and
Reiss, 1993). This has led to the concept that loss of TGF-P
responsiveness is a critical step in epithelial tumour develop-
ment and results in unrestrained tumour cell growth.
TGF-,B signal transduction is mediated through types I, II
and III (P-glycan) TGF-P receptors (Massague, 1992) and,
while defects in TGF-p-receptor profiles have been reported
previously in malignant cell lines (Kimchi et al., 1988;
Segarini et al., 1989), the events distal to legend-receptor
interaction are unclear and anomalies at any point on the
signalling pathway(s) could contribute to loss of TGF-1 res-
ponsiveness. TGF-P1 inhibits c-myc gene transcription
(Coffey et al., 1988; Pietenpol et al., 1990a) and leads to the
arrest of epithelial cells in the late GI phase of the cell cycle
(Munger et al., 1992). The negative effects of TGF-1I on
c-myc transcription have been linked to the phosphorylation
of the RBI-suppressor gene product because viral oncop-
roteins that bind and inactivate pRb also abrogate the res-
ponse of c-myc to TGF-P1 (Pietenpol et al., 1990b). It has
been demonstrated that hyperphosphorylation of pRB at the
GI/S interphase is prevented by TGF-,11 and thus pRb re-
mains in an inactive growth suppressive form (Laiho et al.,
1990a). Other TGF-P1 signal transduction pathways, how-
ever, are likely to exist because TGF-P1 can repress c-myc
transcription independently of functional pRb (Zentella et
al., 1991) and enhance junB transcription in cells indepen-
dently of cell cycle control (Chen et al., 1993). Significantly,
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there is a paucity of information concerning the mechanisms
of TGF-,B signal transduction in human tumour-derived
keratinocytes as apposed to rodent (Coffey et al., 1988) and
genetically manipulated cell lines (Laiho et al., 1990b, 1991);
such data may be more relevant to understanding the role of
TGF-1 in epithelial carcinogenesis.
It has been suggested that the p53 tumour-suppressor gene
may also be involved in TGF-P1 signal transduction. It has
been reported that the majority of malignant epithelial cell
lines are not only resistant to TGF-P1 but also harbour p53
mutations (Fynan and Reiss, 1993), that transfection of
mutant p53 leads to a partial loss of response to TGF-P1 in
human bronchial epithelial cells (Gerwin et al., 1992) and
that TGF-P1 down-regulates p53 expression in the immor-
talised HaCaT keratinocyte cell line (Landesman et al.,
1992). By contrast, there is evidence to show that transfection
of mutant p53 into human cell lines does not necessarily lead
to tumour progression or loss of response to TGF-p1. The
role of p53 in TGF-P signal transduction, therefore, requires
clarification.
We have developed tumour-derived human oral kera-
tinocyte cell lines with a range of biological responses to
TGF-,13, from marked inhibition to complete loss of response
(Prime et al., 1994) and with known ras and p53 gene profiles
(Yeudall et al., 1993, 1995). All of these cell lines express
types I and II TGF-P receptors in varying proportions (Prime
et al., 1994) and, therefore, the possibility remains that
changes in the response of the cell lines to exogenous TGF-
P1 reflect alterations ofgrowth-regulatory genes. The purpose
of the present study was to determine the effects of TGF-1I
on c-myc, RBI, junB and p53 expression, together with Rb
phosphorylation, in normal and tumour-derived keratino-
cytes. This data was examined in the context of the inhibition
of cell proliferation by TGF-P1 and what is previously
known of the genetic abnormalities in these cell lines.
Materials and methods
Cell culture
The growth of keratinocyte cell lines from human oral
squamous cell carcinomas has been described previouslyTGF-p1 nuclear responses
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(Prime et al., 1990; Parkinson and Yeudall, 1991). Normal
human keratinocyte cultures were established from excess
oral mucosa originating from routine oral surgical proce-
dures. Cells were cultured in the presence of 3T3 fibroblast
support using Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (FBS),
0.075% sodium bicarbonate, 0.6 g mI1l L-glutamine,
10lygml-l cholera toxin and 0.5pgml-' hydrocortisone at
37°C in an atmosphere of 95% air, carbon dioxide 5%.
Tumour-derived keratinocytes were cultured in the absence
of 3T3 fibroblasts, cholera toxin and antibiotics after passage
5.
In experiments to examine the effects of TGF-P1 on gene
expression, the growth medium was changed to 1% (v/v)
FBS with or without TGF-P1 (1-10 ng ml-') for the
indicated times. Recombinant TGF-,B1 was purchased from
Austral Biologicals, USA; before use, each batch was tested
by enzyme-linked immunosorbent assay (ELISA) and in
[3H]thymidine incorporation assays.
DNA extraction and Southern blotting
Genomic DNA from cell lines was prepared according the
method of Krieg et al. (1983). After digestion with the appro-
priate restriction enzymes. 10tLg per sample was electro-
phoresed in 0.8% (w/v) agarose gels, transferred to Hybond-
N+ membranes (Amersham) and fixed with 0.4 M sodium
hydroxide for 10-20 min.
Preparation ofRNA and Northern blotting
Total cellular RNA was extracted using a single-step acid
phenol protocol (Chomczynski and Sacchi, 1987) and 20fig
per sample electrophoresed in 0.9% (w/v) agarose gels in the
presence of 0.66 M formaldehyde. The gels were washed in
50 mM sodium hydroxide in 1 x SSC (0.15 M sodium chloride)
for 15 min followed by 10 x SCC for 45 min before transfer
to Hybond-N membranes (Amersham) and the RNA fixed
by baking for 2 h at 80°C. RNA integrity and equal loading
was confirmed by ethidium bromide staining.
Plasmids
The plasmids used for probes were pProSp53 (Matlashewski
et al., 1987) which contains a normal human p53 cDNA
[amplified by polymerase chain reaction (PCR)], pCM41 con-
taining third exon sequences of human c-myc (1.4 kb frag-
ment excised with Clal/EcoRI), pLRbRNL (Su Huang et al.,
1988) containing a normal human RB1 cDNA (0.9 kb frag-
ment excised with EcoRI/BglII) and p465.20 (ATCC) con-
taining a normal mouse junB cDNA (excised with EcoRI).
DNA fragments to be used as probes were gel purified before
oligolabelling with [32P]dCTP (Prime-It II, Stratagene).
Hybridisation conditions
Both Southern and Northern blots were prehybridised over-
night in 5 x SSC, S x Denhardt's, 50 lig ml-' sheared,
denatured salmon sperm DNA and 0.5% (w/v) sodium
dodecyl sulphate (SDS) at 65°C. The blots were probed with
32P-labelled cDNAs for c-myc, RBI, junB or p53 in prehyb-
ridisation solution for 24 h at 65C. Blots were washed twice
in 2 x SSC, 0.1% (w/v) SDS for 15 min at 650C, 1 x SSC,
0.1% (w/v) SDS for 15 min at 65°C and, finally, in
0.5 x SSC, 0.1% (w/v) SDS for 10min at 65°C before
autoradiography.
Western blot analysis
In order to detect Rb protein, cell lysates were prepared by
washing trypsinised cells (x 2) in ice-cold phosphate-buffered
saline (PBS) and resuspending 106 cells in 10 gl of PBS. An
aliquot of 100 ,l of lysis buffer [25 mM Tris-HCI pH 7.4,
50 mM sodium chloride, 0.5% sodium deoxycholate, 2% NP-
40, 0.2% SDS, 50 fig ml-' aprotinin, 50 JLM leupeptin, 1 mM
phenylmethylsulphonyl fluoride (PMSF)] was added to the
cells, the solution was vortexed and then incubated on ice for
15 min with periodic agitation. The cell debris was removed
by microcentrifugation at 13 000 g for 15 min at 4°C and the
proteins separated on a 7.5% (w/v) gel by SDS-polyacryl-
amide gel electrophoresis (PAGE). Proteins were Western
blotted onto Immobilon-P membranes (Millipore), blocked
by overnight incubation in 5% (w/v) dried milk in 25 mM
Tris-HCI (pH 8.0) and 125 mM sodium chloride (block
buffer) at 4°C. Membranes were probed for pRb with anti-
human Rb monoclonal antibody (1:1000 dilution in blocking
buffer; RB245; PharMingen) and overnight incubation at
4°C. The membranes were washed in blocking buffer
(2 x 5 min), Tris-buffered saline (TBS) (2 x 10 min) and
blocking buffer (1 x Omin). The membranes were then
incubated with anti-mouse IgG conjugated with horseradish
peroxidase (1:1000 dilution in blocking buffer; Sigma) for 1 h
at room temperature, washed in blocking buffer (2 x 5 min)
and finally washed in TBS containing 0.1% (v/v) Tween 20
(2 x 10min). Proteins were detected using the enhanced
chemiluminescence (ECL) detection system (Amersham) ac-
cording to the manufacturer's protocol.
For the analysis of c-myc and p53 protein, 1 x 106 cells
were washed in growth medium and then PBS, lysed by
boiling in 1 x sample buffer and the proteins resolved on
10% (w/v) gels by SDS-PAGE. The proteins were detected
as described above except that the monoclonal antibodies
Ab3 for c-myc and PAb 1801 for p53 (both 1:1000 dilution
in blocking buffer; Oncogene Science) were the primary
detection antibodies.
Results
C-myc gene amplification andexpression
In order to determine whether the c-myc locus was amplified
in tumour cells with respect to normal keratinocytes,
Southern hybridisation of genomic DNA was carried out
using a human c-myc third exon probe. In contrast to normal
keratinocytes, amplification of the c-myc gene was observed
in all eight of the tumour-derived cell lines (Figure 1).
In order to determine whether amplification of c-myc
genomic sequences resulted in increased levels of c-myc
mRNA, Northern blot analysis of total cellular RNA was
carried out. As demonstrated in Figure 2, c-myc mRNA
expression was found to correspond to the level of c-myc
gene amplification.
The effect ofTGF-PI on c-myc transcription in the growth
inhibited cell lines H376 and H400 is shown in Figure 3a.
Exposure of all responsive cell lines (including normal
keratinocytes and H357; data not shown) and two of four
partially responsive cell lines (HI57, H413) resulted in a
rapid (1-5 h) down-regulation of c-myc transcription. By
contrast, c-myc transcription was unaltered in H103 and T-45
(partially responsive to TGF-P1) and H314 (refractory to
TGF-P1) cell lines following treatment with exogenous TGF-
P1 (2ngml-') for up to 24h (Figure 3b). Examining the
effect of TGF-P11 (2 ng ml-') for 24 h on c-myc protein exp-
kb
-10
Figure 1 Southern blot analysis of c-myc in tumour-derived
human oral keratinocytes showing gene amplification in all cell
lines compared with normal DNA. Genomic DNA from normal
and tumour-derived keratinocytes (1OIAg) and from the human
promyeocytic leukaemia cell line HL60 (5 1g used as a positive
control) was digested to completion with EcoRI before elect-
rophoresis.
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ression, using Western blot analysis, confirmed the results
obtained by Northern blotting. This is shown in Figure 3c
for H357, H376 (responsive), H103 (partially inhibited) and
H314 (refractory).
Analysis ofRb
Before establishing the effects of TGF-P1 on pRb expression
and phosphorylation patterns, it was necessary to determine
the presence of the RBI gene and ensure its structural inte-
grity. Southern hybridisation of genomic DNA with the RBI
probe revealed that the RBI gene was present in normal
keratinocytes and all tumour-derived cell lines. There was no
evidence of gross structural abnormalities (not shown).
To examine RBI transcription in normal and carcinoma
cells, total RNA was Northern blotted and hybridised with
the RBI cDNA probe. All cell lines expressed RBI mRNA
irrespective of their TGF-i1 phenotype. No alteration to the
levels of RBI transcripts was observed when cells were
a
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exposed to exogenous TGF-,1I (2ngml1l for up to 24h,
data not shown).
As TGF-PI was found to exert no control on RBI trans-
cription, the phosphorylation state of the Rb protein in
response to TGF-P1 was examined by Western blot analysis.
TGF-P1I (10 ng ml-' for 48 h) caused the accumulation of the
underphosphorylated form of the Rb protein in all tumour-
derived keratinocytes. This is shown in Figure 4 for the
markedly growth-inhibited cell line H400, the partially
inhibited cell lines H103, H157 and H413 and the refractory
cell line H314.
Effect ofTGF-P1 onjunB expression
Previous studies have indicated that TGF-P can modulate the
expression of the junB proto-oncogene in cells which are
unresponsive to TGF-p-induced growth inhibition. We
therefore examined the effect of TGF-,11 on junB transcrip-
tion in a growth responsive cell line (H400) and the refrac-
tory cell line (H314) in which TGF-P1 did not down-regulate
c-myc expression. Treatment of the cells with TGF-P1
(2 ngml-') resulted in a rapid (0-2 h) increase in junB exp-
ression (Figure 5).
LO
kb Effect ofTGF-PI exposure on cells expressing normal and mutantp53 species
-2.2 As previous studies have suggested that cells expressing p53
mutants may exhibit an impaired response to TGF-p1, the
effect of TGF-,1I on p53 transcription was investigated by
Northern blot analysis. Exogenous TGF-P1 (2ngml-' for
24 h) did not affect p53 mRNA expression in normal
keratinocytes or in any of the tumour-derived cell lines (data
not shown).
There were no alterations in p53 protein levels in tumour-
derived cell lines (six of eight cell lines) expressing stable p53
protein following treatment with TGF-P1I using 2 ngml' for
24h and lOngml1' for 48h (data not shown). Normal
keratinocytes, H376 and H413 did not express detectable
Figure 2 Northern blot analysis of c-myc mRNA (a), demon-
strating that an increase in gene dosage broadly correlates with
higher transcription levels. Equal loading was confirmed by
ethidium bromide staining (b).
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Figure 4 The effect of TGF-P1I on the phosphorylation state of
the Rb protein, as determined by Western blot analysis. Lysates
were prepared from 1 x 106 cells in the absence (-) or presence
(+) of lOng ml- TGF-P1I for 48 h. An accumulation of under-
phosphorylated pRb was observed in all cell lines in response to
TGF-p1.
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Figure 3 Effect of TGF-P1 on c-myc expression. mRNA levels
were analysed by Northern blotting in the absence (-) or
presence (+) of 2 ngml-' TGF-P1 for 5 h (a) or 24 h (b). c-myc
transcription was down-regulated in all cell lines except H103,
T-45 (partially inhibited) and H314 (refractory) in response to
TGF-p1. Equal loading was confirmed by ethidium bromide
staining (not shown). Similar results were obtained by Western
blot analysis (c). Protein levels were determined in lysates of
1 x 106 cells treated with 2 ngml1 TGF-PI for 24 h.
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Figure 5 Time course of junB transcription in response to
exogenous TGF-pl. mRNA was analysed by Northern blotting in
the absence (-) or presence (+) of 2ngml-' TGF-PI for the
indicated times (h). TGF-PJI enhanced junB transcription in both
H400 (growth inhibited) and H314 (refractory).levels of p53 (Yeudall et al., 1995) and, therefore, TGF-p1-
mediated effects could not be detected.
In addition, the HaCaT keratinocyte cell line (in which
down-regulation of p53 protein expression has been demon-
strated previously following treatment with TGF-p1; Landes-
man et al., 1992) was used as a control in these experiments.
In the present study, no effect on p53 expression was
observed in HaCaT cells in response to TGF-11 exposure.
Discussion
The mechanisms by which TGF-P1 mediate growth inhibition
after binding to specific cell surface receptors remain unk-
nown. In the present study, we have examined the effect of
TGF-P1I on c-myc, RBI, jun B and p53 expression in normal
human oral keratinocytes and tumour-derived cell lines
which exhibit a range of inhibitory responses to TGF-P1
(Prime et al., 1994). The data are summarised in Table I,
together with previously published findings concerning these
cell lines.
In normal human keratinocytes, TGF-P1 reversibly inhibits
cell growth in the late GI phase of the cell cycle (Munger et
al., 1992) and this is thought to be associated with a marked
reduction of c-myc expression (Pietenpol et al., 1990a). In the
present study, all eight tumour-derived cell lines exhibited
c-myc gene amplification and a corresponding increase in
mRNA expression. We have shown previously that six of the
eight cell lines in this study contained isochromosome 8q and
the others harboured increased copies of chromosome 8,
implying an increase in copy number of the c-myc gene
(8q24). The results of the present study are consistent with
previous observations relating c-myc gene amplification to
overexpression (Alitalo et al., 1987). If c-myc levels mediate
the growth inhibitory function of TGF-,1, it might be
expected that overexpression of c-myc protein would enable
tumour cells to overcome TGF-PI-induced growth arrest.
The present study demonstrates that c-myc mRNA overexp-
ression does not abrogate TGF-P1 growth inhibition. Fur-
ther, we demonstrate that c-myc down-regulation by TGF-1I
corresponds to growth inhibition by this ligand in six ofeight
tumour-derived cell lines. In two cell lines which were par-
tially responsive to TGF-01 (H103, T-45), however, c-myc
expression was not down-regulated. These data can be interp-
reted by suggesting that TGF-P1 can inhibit cell cycle pro-
gression outwith c-myc regulation.
The fact that HPV 16 E7, the SV40 T antigen and the
adenovirus Ela protein not only bind and inactivate the
underphosphorylated Rb protein (pRb'05) but also prevent
the down-regulation of c-myc expression by TGF-p1, has led
to the concept that the Rb protein is involved in the trans-
criptional regulation of c-myc by TGF-P1 (Pietenpol et al.,
1990b). In the present study, we examined the presence of the
RBJ gene because previous observations indicated a loss of
chromosome 13, where the RBI gene is located (13q 14.1), in
TGF-p1 nuclear responses
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H314 (Patel et al., 1993). The results of this study demon-
strate that the RBI gene was present in all cell lines, sugges-
ting a chromosome translocation in H314. Whilst RBI
mRNA was unaltered by TGF-p1, the ligand caused the
accumulation of the underphosphorylated form of the Rb
protein in all of the tumour-derived cell lines irrespective of
both the degree of TGF-PI-induced growth inhibition and
TGF-Pl-c-myc down-regulation. Our data indicate that Rb
may not be fundamental to the TGF-p-c-myc pathway and,
in turn, may function independently of ligand-induced
growth inhibition. In H314, for example, the Rb pathway
was intact but the c-myc pathway was abrogated and yet the
cell line continued to cycle in the presence of exogenous
TGF-p1. These findings are in accordance with studies show-
ing down-regulation of c-myc and growth inhibition follow-
ing TGF-P treatment in cells that express a non-functional
pRb (Zentella et al., 1991; Koike et al., 1994). Whether there
is a defect in the signalling pathway between Rb and c-myc
in H314, such that TGF-P1 alters pRb phosphorylation
before c-myc transcription control, is currently not known.
The cell lines used in the present study all contained mutant
p53 (Yeudall et al., 1995) indicating that the cyclin D-cdk4
and cyclin E-cdk2 pathways, which are p53 dependent
(Hunter and Pines, 1994; Ewen et al., 1995), are likely to be
non-functional. TGF-B13, therefore, is likely to regulate Rb
phosphorylation independently of these pathways. The ques-
tion of how TGF-3 regulates c-myc down-regulation
independently of Rb phosphorylation and how TGF-p-
induced growth control can occur independently of c-myc
regulation remains an enigma. One possible mechanism is the
regulation of the cell cycle via the cyclin-inhibitory protein
p21, which binds and inactivates components of the DNA
replicatory machinery (Waga et al., 1994); interestingly,
recent data indicate that p21 acts independently of p53
(Parker et al., 1995).
The results of the present study indicate that control of
junB expression is also independent of cellular proliferation,
confirming previous observations in mink lung epithelial cells
(Chen et al., 1993). TGF-P is known to bind to three high-
affinity cell surface receptors termed types I, II and III
(Massague, 1992). It has previously been demonstrated that
both type I and II receptors are required for TGF-P signall-
ing (Laiho et al., 1990b; Wrana et al., 1992). Extending these
findings, Chen et al. (1993) have proposed that there are
different TGF-P1 signalling pathways mediated by type I and
II receptors, the former involving the induction of junB
expression and the elaboration of extracellular matrices and
the latter including c-myc down-regulation and inhibition of
cell growth. It is tempting to speculate that both junB and
Rb are involved in signalling pathways leading to extracel-
lular matrix (ECM) elaboration, but this obviously requires
experimental confirmation. All the cell lines in the present
study express both type I and II receptors in variable propor-
tions (Prime et al., 1994). Our results indicate that the expres-
sion of one specific TGF-, receptor does not correlate with
Table I Characteristics of tumour-derived human oral keratinocytes
TGF-I3C TGF-pJ- TGF-PI-mediated Ha-Ras
response mediated accwnulation of mutation (codon) p53 mutation codon
Cell (Prime et al., c-myc underphos- (Yeudall et al., (exon)
line Diferentiationa Tumorigenicityb 1994) down-regulation phorylated pRB 1993) (Yeudall et al., 1995)
Normal - NT + + + + + - -
103 M T + - + - 244 (7) G-T
157 M NT + + + - 306 (8) G-A
314 p T - _ + - 176 (5) G-T,373(11)A-G
357 W T +++ + + 13 G-A, 61 A-G 110 (4) G-A
376 M NT + + + + + - 266 (8) G-T
400 M NT + + + + + - 283 (8) C-G
413 W NT + + + - 68 (4) A-G
T-45 ND T + - + - 110 (4) G-T
aKeratin profiles of differentiation: W, well-differentiated; M, moderately differentiated; P, poorly differentiated; ND, not done.
bApproximately 1 x 107cells were transplanted subcutaneously into 4- to 6-week-old male athymic (nu/nu; Balb/C) mice. Animals were killed
following tumour formation or after 6 months. T, tumorigenic; NT, non-tumorigenic. cCellular response to exogenous TGF-PI as determined
by [3H]thymidine incorporation assays. + + +, Markedly inhibited; +, partially inhibited; -, refractory.TGF-P1 nudear responses
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the control of c-myc, Rb or junB but do not exclude the
possibility of interdependent receptors with separate signall-
ing pathways. The possibility of divergent receptor-mediated
TGF-, signal transduction mechanisms, however, is currently
being questioned (Weiser et al., 1994; Wrana et al., 1994) and
is likely to be an area of intense study in the future.
We have demonstrated previously that all of the cell lines
in the present study contain mutant p53 in either a missense
(H103, H314, H357, H400, H413, T-45) or nonsense (H157,
H376) form. The fact that the nonsense mutations in H157
and H376 resulted in a truncated protein (Yeudall et al.,
1995) eand the cells are markedly inhibited by TGF-P1 (Prime
et al., 1994) indicates that p53-independent pathways are
likely to be involved in TGF-P signal transduction. This
conclusion differs from previous observations (Gerwin et al.,
1992; Landesman et al., 1992) and, indeed, Landesman et al.
(1992) demonstrated a reduction in p53 protein levels in the
immortalised human HaCaT keratinocyte cell line following
TGF-P1 treatment. In the present study, TGF-P1 did not
alter p53 protein levels in either the tumour-derived
keratinocyte cell lines or the HaCaT cell line. Whether the
discrepancies between the results of the present study and
those of Landesman et al. (1992) reflect culture conditions
and/or the use of different monoclonal antibodies (present
study, PAb 1801; Landesman et al., 1992 PAb 421), both of
which detect mutant and wild-type p53, is currently not
known.
The relationship between activation of ras genes and the
cellular responsiveness to TGF-,B is unclear. We have shown
previously that transfection of the mutant cellular Ha-ras
gene into the human immortalised HaCaT keratinocyte line
resulted in a progressive loss of response to TGF-P1 (Game
et al., 1992), findings that are entirely consistent with p21-ras
being involved in TGF-,11 signal transduction (Howe et al.,
1993). The results of the present study indicate that TGF-P1
can inhibit epithelial cell growth despite the presence of
Ha-ras mutations (H357); previous studies have shown the
presence of viral and cellular mutant ras gene in TGF-,B-
sensitive cell lines (Manning et al., 1991; Missero et al.,
1991). The data of the present study indicate that TGF-P1
signal transduction can occur independently of ras mutation
and support the findings of Yan et al. (1994) showing that
TGF-P1 can activate two different signal transduction path-
ways, one ras dependent and another ras independent.
Elucidating the mechansims that control the cell cycle is
fundamental to an understanding of cell behaviour and
malignancy. The results of the present study indicate that
TGF-p-induced growth control can exist independently of the
presence of mutant p53 and the control of Rb phosphoryla-
tion and c-myc down-regulation in tumour-derived human
oral keratinocytes. Taken together, the results suggest that
multiple mechanisms control TGF-,B growth inhibition and
that the abrogation of one pathway does not necessarily lead
to loss of TGF-B-induced growth control.
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